[Firefly Neuroscience in GlobeNewswire] STALICLA and Firefly Neuroscience enter partnership agreement for the development of Electroencephalogram (EEG) as a biomarker for subgroups of patients with ASD

Geneva, Switzerland – 27 March 2023, STALICLA SA and Firefly Neuroscience today announced a partnership to further validate EEG-based biomarkers in biologically enriched subgroups of patients with Autism Spectrum Disorder (ASD). This follows the successful completion of STALICLA’s Phase 1b clinical trial for its lead asset STP1 where EEG measurement was shown to be a powerful predictor of efficacy.

Read more here.